Morning Glory Sciences– Author –
After completing graduate school, I studied at a Top tier research hospital in the U.S., where I was involved in the creation of treatments and therapeutics in earnest. I have worked for several major pharmaceutical companies, focusing on research, business, venture creation, and investment in the U.S. During this time, I also serve as a faculty member of graduate program at the university.
-
Beginner's series tissue specific tumor
Cancer Worries Episode 7 — Ovarian Cancer: 4 Points to Organize When Facing a Late-Detection Diagnosis
“I’m constantly bloated.” “I feel full quickly.” “I’m going to the bathroom more often.” Ovarian cancer is a topic where uncertainty can quickly fuel “I’m constantly bloated.” “I feel full quickly.” “I’m going to the bathroom more often.... -
Beginner's series tissue specific tumor
Cancer Worries Episode 6 — Pancreatic Cancer: Reading the Treatment Map When Survival Numbers Feel Heavy
“Pancreatic cancer is hard to detect.” “Symptoms are vague.” That uncertainty often fuels anxiety and a deep search spiral. “Pancreatic cancer is hard to detect.” “Symptoms are vague.” That uncertainty often fuels anxiety and a deep sear... -
Oncology FDA Approval
Zongertinib FDA承認 (Boehringer Ingelheim): What the HER2 TKD Approval Means for NSCLC Sequencing
FDA approval summary On February 26, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the kinase inhibitor zongertinib (Hernexeos, Boehringer Ingelheim) for an expanded indication in adult patients with u... -
Oncology FDA Approval
BRAF V600E CRC: What FDA’s Endorsement of Encorafenib + Cetuximab + Chemo Reshapes in 1L
FDA approval summary On February 24, 2026, the U.S. Food and Drug Administration (FDA) granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorourac... -
Beginner's series tissue specific tumor
Cancer Worries Episode 5 — Prostate Cancer: 5 Decision Points from Active Surveillance to Advanced Treatment
“My PSA is high.” “My PSA keeps creeping up.” “They told me to repeat the test.” Prostate cancer often starts with a number, which can easily amplify “My PSA is high.” “My PSA keeps creeping up.” “They told me to repeat the test.” Prosta... -
Beginner's series tissue specific tumor
Cancer Worries Episode 3 — Metastasis: 4 Frames for Understanding How Cancer Spreads and What That Changes
“My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening result says I need follow-up.” “I tested positive for H. pylori.” St “My stomach feels uncomfortable.” “I’ve had indigestion for weeks.” “My screening resu... -
Beginner's series tissue specific tumor
Cancer Worries Episode 4 — Breast Cancer: 4 Subtype Pathways That Shape Today’s Personalized Treatment
“Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer searches can quickly become overwhelming. “Is this a lump?” “Why does this side look different?” “There’s nipple discharge.” Breast cancer s... -
Beginner's series tissue specific tumor
Cancer Worries Episode 2 — Colorectal Cancer: 5 Checkpoints That Reshape the Path from Screening to Treatment
“I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool test came back positive.” Once you start searching, the amount of i “I noticed blood in my stool.” “My bowel habits have changed.” “My screening stool tes... -
Beginner's series tissue specific tumor
Cancer Worries Episode 1 — Lung Cancer: 4 Decision Axes That Open the Modern Treatment Landscape
“My cough won’t go away.” “I get short of breath.” “My health check X-ray showed a shadow.” Once you start searching, it’s easy to get overwhelmed and “My cough won’t go away.” “I get short of breath.” “My health check X-ray showed a sha... -
Beginner-friendly
Untangling Cancer Worries — Your First Guide, Part 8|Lung Cancer Basics: A Calm One-Page Map of Tests, Staging, and Treatment in 3 Steps (With When-to-Seek-Care Signs)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstCommon entr... -
Beginner-friendly
Cancer Worries Guide Part 7 — Breakthrough Treatments: Reading 5 Modalities Reshaping Modern Oncology
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstThe three t... -
Beginner-friendly
Untangling Cancer Worries — Your First Guide, Part 6|What Is a Rare Cancer? 3 Ways to Search When Information Is Limited (and What to Ask Clinicians)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is a “... -
Oncology FDA Approval
Optune Pax FDA承認: What Tumor Treating Fields Add to Locally Advanced Pancreatic Care
FDA approval summary On February 11, 2026, the U.S. Food and Drug Administration (FDA) approved a low electric field generator device, Optune Pax (Novocure), in combination with gemcitabine and nab-paclitaxel for the treatment of adult p... -
Beginner-friendly
Untangling Cancer Worries — Your First Guide, Part 5|Genetic Variants and Cancer Risk: 3 Things Tests Can Tell You (and What They Can’t)
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Beginner-friendly
Untangling Cancer Worries — Your First Guide, Part 4|Benign vs Malignant Tumors: 3 Things to Confirm First Without Being Misled by the Words
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat does “... -
Beginner-friendly
Untangling Cancer Worries — Your First Guide, Part 3|What Does “Metastasis” Mean? 3 Differences From Stage and How Treatment Plans Can Change
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to confirm firstWhat is met... -
Oncology FDA Approval
Platinum-Resistant Ovarian: Reading FDA’s Approval of Pembrolizumab + Paclitaxel ± Bevacizumab
FDA approval summary On February 10, 2026, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) and pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with... -
Beginner-friendly
Cancer Worries Guide Part 2 — If Cancer Crosses Your Mind: 4 Steps to Organize Worry into Action
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (the quick answer)To calm down: the “one thing” to do firstThree things to ch... -
Beginner-friendly
Cancer Worries Guide Part 1 — When Diagnosed: 5 First Conversations to Anchor Your Treatment Path
Series: Untangling Cancer Worries — Your First Guide Series: Untangling Cancer Worries — Your First Guide What you will learn What you’ll get from this article (quick answer)To steady yourself: the “one thing” to do in the first 24 hours... -
AI Drug Discovery
From Beginner to Expert: AI in Drug Discovery – A Definitive Guide from Lab to Market (Extra Chapter, Snapshot as of November 22, 2025) focuses only on the latest AI-driven case studies and summarizes how far AI has actually progressed in real drug discovery and development.
1. Where Does AI in Drug Discovery Stand in 2025? Between 2024 and 2025, AI in drug discovery has quietly moved from the “proof-of-concept” phase into a stage where AI-designed molecules are showing signals in human trials. Between 2024 ...